Clinical and Experimental Vaccine Research  2012;1(1):50-63

doi:10.7774/cevr.2012.1.1.50

Mucosal vaccine adjuvants update.

Joon Haeng RHEE 1 ; Shee Eun LEE ; Soo Young KIM

Affiliations

+expand

Keywords

Mucosal; Vaccine; Adjuvant; Innate immunity

Country

Republic of Korea

Language

English

Abstract

Mucosal vaccination, capable of inducing protective immune responses both in the mucosal and systemic immune compartments, has many advantages and is regarded as a blue ocean in the vaccine industry. Mucosal vaccines can offer lower costs, better accessability, needle-free delivery, and higher capacity of mass immunizations during pandemics. However, only very limited number of mucosal vaccines was approved for human use in the market yet. Generally, induction of immune responses following mucosal immunization requires the co-administration of appropriate adjuvants that can initiate and support the effective collaboration between innate and adaptive immunity. Classically, adjuvant researches were rather empirical than keenly scientific. However, during last several years, fundamental scientific achievements in innate immunity have been translated into the development of new mucosal adjuvants. This review focuses on recent developments in the concepts of adjuvants and innate immunity, mucosal immunity with special interest of vaccine development, and basic and applied researches in mucosal adjuvant.